Non-Hodgkin Lymphoma Clinical Trials
Non-Hodgkin Lymphoma clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for non-Hodgkin Lymphoma. Corterve aggregates actively recruiting Non-Hodgkin Lymphoma studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Non-Hodgkin Lymphoma studies
- A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin LymphomaNCT05533775PHASE1, PHASE2Hoffmann-La RocheMature B-Cell Non-Hodgkin LymphomaBirmingham, Alabama
- Emapalumab Prevention of CAR-T Cell Associated ToxicitiesNCT06550141PHASE2Marcela V. Maus, M.D.,Ph.D.Large B-cell LymphomaBoston, Massachusetts
- Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology ClinicsNCT06418204Wake Forest University Health SciencesBreast CarcinomaFairbanks, Alaska
- Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaNCT05672251PHASE2City of Hope Medical CenterRecurrent Diffuse Large B-Cell LymphomaDuarte, California
- Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaNCT07283679PHASE1, PHASE2M.D. Anderson Cancer CenterRecurrent B-Cell Non-Hodgkin LymphomaHouston, Texas
- A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)NCT06173518PHASE1Autolus LimitedRelapsed or Refractory B Cell Acute Lymphoblastic LeukemiaAurora, Colorado
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesNCT05006716PHASE1, PHASE2BeOne MedicinesB-cell MalignancyBirmingham, Alabama
- Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin LymphomaNCT07763210PHASE2Vanderbilt-Ingram Cancer CenterNon-hodgkin LymphomaNashville, Tennessee
- Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyNCT06834373PHASE2Mayo ClinicLarge B-Cell Lymphoma With IRF4 RearrangementScottsdale, Arizona
- Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaNCT04803201PHASE2Alliance for Clinical Trials in OncologyAngioimmunoblastic T-cell LymphomaLittle Rock, Arkansas
- Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)NCT01853631PHASE1Baylor College of MedicineNon-Hodgkin LymphomaHouston, Texas
- A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHLNCT03571568PHASE1, PHASE2BioInvent International ABIndolent B-Cell Non-Hodgkin LymphomaAtlanta, Georgia
Non-Hodgkin Lymphoma trials by state
Non-Hodgkin Lymphoma trials by metro
Frequently asked questions
- How do I find recruiting Non-Hodgkin Lymphoma clinical trials?
- Browse the actively recruiting Non-Hodgkin Lymphoma studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.
- Are Non-Hodgkin Lymphoma clinical trials free to join?
- Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.
- Who can take part in a Non-Hodgkin Lymphoma clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.